Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Daniel O'Day
Age : 56
Public asset : 9,388,479 USD
Country of residence : Unknown
Linked companies : Gilead Sciences, Inc. - Galapagos NV

Summary 
Mr. Daniel P. O'Day is a Chairman & Chief Executive Officer at Gilead Sciences, Inc.

He is on the Board of Directors at Galapagos NV, Flatiron Health, Inc., Pharmaceutical Manufacturers Association of America, Pharmaceutical Research & Manufacturers of America and Shanghai Roche Pharmaceuticals Ltd. Mr. O'Day was previously employed as a President & Chief Executive Officer by Roche Molecular Systems, Inc., a General Manager by Roche A/S Medicinalvarer OG Kemikalier, a Chief Operating Officer by Roche Diagnostics A/S, a Head-Business Unit, Arthritis & Respiratory by Roche Pharma Schweiz AG, a Chief Executive Officer by Roche Pharmaceuticals, Inc., a Head-Corporate Planning by Roche Diagnostics KK, and a CEO-Roche Pharmaceuticals by Roche Holding AG.

He also served on the board at Foundation Medicine, Inc., Chugai Pharmaceutical Co., Ltd., Genentech, Inc. and Roche Diagnostics GmbH.

He received his undergraduate degree from Georgetown University and an MBA from The Trustees of Columbia University in The City of New York.




Current positions of Daniel O'Day 
Holdings of Daniel O'Day 
Daniel O'Day : Personal Network 
Most Read News 
06/14ELON MUSK : Bitcoin tops $40,000 after Musk says Tesla could use it again
RE
06/12JEFF BEZOS : Bid of $28 million wins a rocket trip to space with Bezos
RE
07:22aRAJESH KUMAR : Pass them on
RE
06/18PETER THIEL : Thiel-backed psychedelics startup Atai valued at $3.19 billion in Nasdaq debut
RE
06/11ELON MUSK : 'This car crushes' Musk says, as Tesla launches faster Model S 'Plaid'
RE
04:58pWARREN BUFFETT : Warren Buffett resigns from Gates Foundation, has donated half his fortune
RE
06/15JACK MA : Alibaba executive says founder Jack Ma 'lying low' - CNBC
RE
06/21WARREN BUFFETT : Buffett-backed Nubank in talks to hire U.S. IPO underwriters -sources
RE
06/10MARIA MARTINEZ : French Industrial Production Unexpectedly Declined in April
DJ
06/22ALIKO DANGOTE : Nigeria's Dangote to start exporting fertiliser to U.S., Brazil
RE
More news


© 2021 People and Ownership :   
Daniel O'Day : Connections 


Latest news about Daniel O'Day 
02/04GILEAD SCIENCESá : Sells $1.94 Billion In Covid-19 Treatment, Bolstering 4Q Performance
DJ
01/11Gilead Lifts Guidance as Remdesivir Sales Surge; CEO Expects Treatment to Be Effective Against New Coronavirus Strains
MT
2020GILEAD SCIENCESá : to acquire German biotech firm MYR for about 1.15 billion euros
RE
2020GILEAD SCIENCESá : to Pay $1.4 Billion for Hepatitis Drug Maker MYR GmbH of Germany
DJ
2020Gilead Quarterly Revenue Rises on Remdesivir Sales -- Update
DJ
2020GILEAD SCIENCESá : Quarterly Revenue Rises on Remdesivir Sales
DJ
2020Covid-19 Drug Remdesivir Fully Approved by FDA
DJ
More news